FENC
Fennec Pharmaceuticals Inc.NASDAQHealthcare$6.42+0.16%ClosedMarket Cap: $183.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.71
P/S
4.09
EV/EBITDA
-23.01
DCF Value
$-11.06
FCF Yield
-6.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.5%
Operating Margin
-15.1%
Net Margin
-22.7%
ROE
-236.4%
ROA
-14.5%
ROIC
-11.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $14.0M | 87.2% | $-3.1M | $-5.2M | $-0.17 | — |
| FY 2025 | $45.4M | 91.6% | $-6.9M | $-10.3M | $-0.36 | — |
| Q3 2025 | $12.5M | 94.7% | $-189.0K | $-638.0K | $-0.02 | — |
| Q2 2025 | $9.7M | 90.0% | $-2.7M | $-3.2M | $-0.12 | — |
| Q1 2025 | $8.8M | 95.7% | $-808.0K | $-1.2M | $-0.04 | — |
| Q4 2024 | $7.9M | 91.6% | $-934.0K | $-2.0M | $-0.06 | — |
| FY 2024 | $47.5M | 93.3% | $2.6M | $-436.0K | $-0.02 | — |
| Q3 2024 | $7.0M | 80.5% | $-5.2M | $-5.7M | $-0.21 | — |
| Q2 2024 | $7.3M | 91.6% | $-5.0M | $-5.6M | $-0.20 | — |
| Q1 2024 | $25.4M | 97.8% | $13.7M | $12.8M | $0.41 | — |
| Q4 2023 | $10.0M | 93.0% | $-1.9M | $-2.8M | $-0.10 | — |
| FY 2023 | $21.3M | 94.1% | $-12.8M | $-16.0M | $-0.60 | — |